Business Context and Reporting Period
Company: Lucid Diagnostics Inc. (LUCD)
Filing Type: Form 8-K (Current Report)
Date of Report: June 21, 2024
Context: The Company is an emerging growth company incorporated in Delaware. This filing addresses a regulatory notice regarding the continued listing of its common stock on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a listing compliance issue.
Material Changes
- Stock Price Deficiency: The Company received notice from Nasdaq that its common stock closing bid price was below the minimum requirement of $1.00 per share for 30 consecutive business days ending June 20, 2024.
- Listing Status: The stock remains listed and continues to trade under the symbol "LUCD" without interruption at this time.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day period (until December 18, 2024) to regain compliance.
- Compliance Requirement: To cure the deficiency, the closing bid price must be at least $1.00 for a minimum of 10 consecutive business days.
- Future Options: If compliance is not met within the initial 180 days, the Company may be eligible for an additional 180-day period. Failure to cure the deficiency or ineligibility for an extension could result in delisting.
- Management Action: The Company intends to consider all available options to regain compliance with Nasdaq listing standards.
Investor Verification Checklist
- Verify the current trading price of LUCD to assess the gap from the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to determine if the initial cure period is met.
- Review future filings for announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Track the December 18, 2024 deadline for the initial compliance period.